Matthew E. Levison

25.2k total citations · 8 hit papers
141 papers, 14.8k citations indexed

About

Matthew E. Levison is a scholar working on Epidemiology, Infectious Diseases and Pharmacology. According to data from OpenAlex, Matthew E. Levison has authored 141 papers receiving a total of 14.8k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Epidemiology, 53 papers in Infectious Diseases and 42 papers in Pharmacology. Recurrent topics in Matthew E. Levison's work include Antibiotics Pharmacokinetics and Efficacy (40 papers), Antibiotic Resistance in Bacteria (35 papers) and Antimicrobial Resistance in Staphylococcus (35 papers). Matthew E. Levison is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (40 papers), Antibiotic Resistance in Bacteria (35 papers) and Antimicrobial Resistance in Staphylococcus (35 papers). Matthew E. Levison collaborates with scholars based in United States, France and Canada. Matthew E. Levison's co-authors include Kathryn A. Taubert, Ann F. Bolger, Michael H. Gewitz, Larry M. Baddour, Jane W. Newburger, Donald Kaye, Walter R. Wilson, Stanford T. Shulman, Robert S. Baltimore and Thomas J. Pallasch and has published in prestigious journals such as New England Journal of Medicine, JAMA and Circulation.

In The Last Decade

Matthew E. Levison

140 papers receiving 13.9k citations

Hit Papers

Infective Endocarditis in... 1997 2026 2006 2016 2015 2004 2005 2004 1997 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications
    2015 1.9k citations Larry M. Baddour, Walter R. Wilson et al. Circulation profile →
  2. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease
    2004 1.4k citations Jane W. Newburger, Masato Takahashi et al. Circulation profile →
  3. Infective Endocarditis
    2005 1.2k citations Larry M. Baddour, Walter R. Wilson et al. Circulation profile →
  4. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association
    2004 990 citations Jane W. Newburger, Masato Takahashi et al. profile →
  5. Prevention of bacterial endocarditis. Recommendations by the American Heart Association
    1997 776 citations Kathryn A. Taubert, Walter R. Wilson et al. profile →
  6. Periodontal Disease and Atherosclerotic Vascular Disease: Does the Evidence Support an Independent Association?
    2012 770 citations Peter B. Lockhart, Ann F. Bolger et al. Circulation profile →
  7. Update on Cardiovascular Implantable Electronic Device Infections and Their Management
    2010 700 citations Larry M. Baddour, Andrew E. Epstein et al. Circulation profile →
  8. Vascular Graft Infections, Mycotic Aneurysms, and Endovascular Infections: A Scientific Statement From the American Heart Association
    2016 302 citations Walter R. Wilson, Patrick T. O’Gara et al. Circulation profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Matthew E. Levison 7.2k 4.7k 4.3k 3.2k 2.9k 141 14.8k
Larry M. Baddour 13.4k 1.9× 7.6k 1.6× 8.5k 2.0× 5.2k 1.6× 6.0k 2.1× 456 25.1k
Robert P. Gaynes 6.1k 0.9× 6.0k 1.3× 7.2k 1.7× 2.1k 0.7× 1.8k 0.6× 131 22.8k
James M. Steckelberg 10.1k 1.4× 10.9k 2.3× 6.7k 1.6× 4.0k 1.2× 3.2k 1.1× 230 21.6k
Walter R. Wilson 5.8k 0.8× 2.2k 0.5× 3.4k 0.8× 2.8k 0.9× 2.7k 0.9× 146 9.6k
David H. Culver 5.1k 0.7× 4.1k 0.9× 5.6k 1.3× 1.8k 0.6× 1.3k 0.5× 92 16.2k
Adolf W. Karchmer 6.8k 0.9× 3.6k 0.8× 9.9k 2.3× 4.2k 1.3× 1.2k 0.4× 159 19.7k
Stanford T. Shulman 6.5k 0.9× 10.7k 2.3× 5.6k 1.3× 6.8k 2.1× 4.2k 1.5× 357 22.0k
Peter B. Lockhart 5.0k 0.7× 3.2k 0.7× 2.8k 0.7× 2.8k 0.9× 2.9k 1.0× 158 12.6k
Daniel M. Musher 17.3k 2.4× 2.9k 0.6× 6.9k 1.6× 2.9k 0.9× 879 0.3× 340 26.9k
Arnold S. Bayer 10.6k 1.5× 3.1k 0.6× 16.3k 3.8× 7.1k 2.2× 2.0k 0.7× 372 27.7k

Countries citing papers authored by Matthew E. Levison

Since Specialization
Citations

This map shows the geographic impact of Matthew E. Levison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew E. Levison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew E. Levison more than expected).

Fields of papers citing papers by Matthew E. Levison

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew E. Levison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew E. Levison. The network helps show where Matthew E. Levison may publish in the future.

Co-authorship network of co-authors of Matthew E. Levison

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew E. Levison. A scholar is included among the top collaborators of Matthew E. Levison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew E. Levison. Matthew E. Levison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Baddour, Larry M., Walter R. Wilson, Arnold S. Bayer, et al.. (2015). Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications. Circulation. 132(15). 1435–1486. 1919 indexed citations breakdown →
2.
Lockhart, Peter B., Ann F. Bolger, Panos N. Papapanou, et al.. (2012). Periodontal Disease and Atherosclerotic Vascular Disease: Does the Evidence Support an Independent Association?. Circulation. 125(20). 2520–2544. 770 indexed citations breakdown →
3.
Baddour, Larry M., Andrew E. Epstein, Christopher C. Erickson, et al.. (2010). Update on Cardiovascular Implantable Electronic Device Infections and Their Management. Circulation. 121(3). 458–477. 700 indexed citations breakdown →
4.
Levison, Matthew E. & Julie H. Levison. (2009). Pharmacokinetics and Pharmacodynamics of Antibacterial Agents. Infectious Disease Clinics of North America. 23(4). 791–815. 400 indexed citations
5.
Levison, Matthew E., et al.. (2006). Community-associated methicillin-resistant Staphylococcus aureus: Reconsideration of therapeutic options. Current Infectious Disease Reports. 8(1). 23–30. 8 indexed citations
6.
Baddour, Larry M., Walter R. Wilson, Arnold S. Bayer, et al.. (2005). Infective Endocarditis. Circulation. 111(23). e394–434. 1204 indexed citations breakdown →
7.
Levison, Matthew E.. (2004). Pharmacodynamics of antimicrobial drugs. Infectious Disease Clinics of North America. 18(3). 451–465. 208 indexed citations
8.
9.
Ferrieri, Patricia, Michael H. Gewitz, Michael A. Gerber, et al.. (2002). Unique Features of Infective Endocarditis in Childhood. Circulation. 105(17). 2115–2126. 176 indexed citations
10.
Tompkins, Lucy S., Julius Schachter, Jens Boman, et al.. (2000). Collaborative Multidisciplinary Workshop Report: Detection, Culture, Serology, and Antimicrobial Susceptibility Testing ofChlamydia pneumoniae. The Journal of Infectious Diseases. 181(s3). S460–S461. 18 indexed citations
11.
Levison, Matthew E.. (2000). PHARMACODYNAMICS OF ANTIBACTERIAL DRUGS. Infectious Disease Clinics of North America. 14(2). 281–291. 30 indexed citations
12.
Dajani, Adnan S., Kathryn A. Taubert, Walter R. Wilson, et al.. (1997). PREVENTION OF BACTERIAL ENDOCARDITIS: RECOMMENDATIONS BY THE AMERICAN HEART ASSOCIATION. The Journal of the American Dental Association. 128(8). 1142–1151. 123 indexed citations
13.
Johnson, Caroline C., et al.. (1997). Peritonitis: Update on Pathophysiology, Clinical Manifestations, and Management. Clinical Infectious Diseases. 24(6). 1035–1045. 75 indexed citations
14.
Abrutyn, Elías, Jesse A. Berlin, Jana Mossey, et al.. (1996). Does Treatment of Asymptomatic Bacteriuria in Older Ambulatory Women Reduce Subsequent Symptoms of Urinary Tract Infection?. Journal of the American Geriatrics Society. 44(3). 293–295. 35 indexed citations
15.
Johnson, Christine Cole, et al.. (1995). Activity of cefepime against ceftazidime-resistant Gram-negative bacilli using low and high inocula. Journal of Antimicrobial Chemotherapy. 35(6). 765–773. 28 indexed citations
16.
Berlin, Jesse A., Elías Abrutyn, Brian L. Strom, et al.. (1995). Incidence of infective endocarditis in the Delaware Valley, 1988–1990. The American Journal of Cardiology. 76(12). 933–936. 120 indexed citations
17.
Levison, Matthew E., et al.. (1993). The bactericidal activity of magainins against Pseudomonas aeruginosa and Enterococcus faecium. Journal of Antimicrobial Chemotherapy. 32(4). 577–585. 10 indexed citations
18.
Levison, Matthew E., et al.. (1991). Host Defense Mechanisms in the Pathogenesis of Urinary Tract Infection. Medical Clinics of North America. 75(2). 275–286. 20 indexed citations
19.
Wendeler, Michaela, et al.. (1991). Synergistic Bactericidal Activity of Rat Serum with Vancomycin against Enterococci. The Journal of Infectious Diseases. 163(6). 1358–1361. 13 indexed citations
20.
Abrutyn, Elías, Jana Mossey, Matthew E. Levison, et al.. (1991). Epidemiology of Asymptomatic Bacteriuria in Elderly Women. Journal of the American Geriatrics Society. 39(4). 388–393. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Larry M. Baddour Breakdown of academic impact, for papers by Robert P. Gaynes Breakdown of academic impact, for papers by James M. Steckelberg Breakdown of academic impact, for papers by Walter R. Wilson Breakdown of academic impact, for papers by David H. Culver Breakdown of academic impact, for papers by Adolf W. Karchmer Breakdown of academic impact, for papers by Stanford T. Shulman Breakdown of academic impact, for papers by Peter B. Lockhart Breakdown of academic impact, for papers by Daniel M. Musher Breakdown of academic impact, for papers by Arnold S. Bayer
Rankless by CCL
2026